CSL300 Safety Study for Kidney Dialysis Patients
Part of Heart & circulation, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests how a new drug called CSL300 (clazakizumab) works in the body of people with end-stage kidney disease who are on dialysis. Researchers want to understand if it's safe and how your body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have end-stage kidney disease and have been on maintenance dialysis for at least 12 weeks
- You are willing to follow all study procedures and attend appointments
- You do not have active infections, including TB, HIV, hepatitis B or C, or serious fungal infections
- You have not had major surgery in the past 3 months and do not have a kidney transplant planned in the next 6 months
- You do not have a history of stomach or bowel problems like ulcers, inflammatory bowel disease, or diverticulitis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests three experimental antibodies given to people with end-stage kidney disease who are on hemodialysis. It aims to see if these drugs are safe and how they affect blood clotting in this group.
This study tests different treatments for people with advanced kidney disease, including those on dialysis or with a kidney transplant. It aims to find better ways to manage the condition and improve outcomes.
This study tests an experimental drug called KN060, given to people with end-stage kidney disease on dialysis, to see if it is safe and helps with blood clotting. It may be an option if you are on stable dialysis and not at high risk for bleeding.
This trial tests whether adding a special filter called pHA130 to your regular dialysis treatments can better remove certain waste products from your blood and improve your quality of life. It's for people who have been on dialysis for at least 3 months and meet a few health requirements.
This study tests a new medicine called AP303 for people with type 2 diabetes and chronic kidney disease. The goal is to see if it is safe and how the body processes it. If you have diabetes and your kidneys are not working as well as they used to, this trial might help find new treatment options.
This study tests an experimental drug called clazakizumab (CSL300) to see if it can reduce inflammation and lower the risk of heart problems in people with kidney failure who are on dialysis. It may help if you have diabetes or heart disease and have high inflammation levels.
Hear when a new End Stage Kidney Disease (ESKD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.